The Leukemia & Lymphoma Society has awarded a $971,484 Screen to Lead grant to University of North Carolina Lineberger Comprehensive Cancer Center researchers to launch an investigation of new drug compounds that would block enzymes that can become hyperactive in blood cancer cells when mutated. UNC Lineberger’s John Sondek, PhD, a professor in the UNC … Continued
Jack Goldstein, 14, and his family had to make sacrifices when Jack was diagnosed with leukemia. But when Jack put his schoolwork and baseball training on hold, his family and friends were there to support him, first emotionally, and then by helping raise funds for UNC Lineberger, where he was being treated for cancer.
Lorelei Partin’s cancer journey has led her mom, Katie Ware, to discover a whole new community of friends and a hidden talent for fundraising along the way. Diagnosed two years ago, Lorelei cannot wait to ring the bell to mark the end of her leukemia treatments, but she’s going to miss the people at the N.C. Cancer Hospital’s Pediatric Hematology Oncology Clinic, including her doctor, UNC Lineberger’s Thomas Alexander, MD, MPH.
UNC Lineberger’s Joshua Zeidner, MD, reported preliminary data at the 60th American Society of Hematology Annual Meeting from a phase II clinical trial for administering a high-dose of the chemotherapy treatment cytarabine followed by an immune checkpoint inhibitor, pembrolizumab, in patients with acute myeloid leukemia that had relapsed or no longer responded to other treatment.
Etteinne “ET” and W. G. Champion “Champ” Mitchell of New Bern, North Carolina, will create a new fund supporting ground-breaking research in blood cancer at UNC Lineberger Comprehensive Cancer Center, including lymphoma, leukemia and myeloma research, in gratitude for the care Champ received and to bolster research directed at finding cures.
In the journal Blood Advances, UNC Lineberger’s Ben Vincent, MD, Paul Armistead, MD, PhD, and their collaborators reported early findings from a new study that could aid in the development of immune-based treatments that are tailored to individual leukemia patients who are undergoing stem cell transplantation.